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Abstract. Human insulin-like growth factor I and II 
(IGF-I and IGF-II) in concentrations of 1-30 ng/ml, 
were shown to stimulate ornithine decarboxylase ac- 
tivity and [3H]thymidine incorporation in human SH- 
SY5Y neuroblastoma cells. Proliferation of these cells 
was also stimulated by IGF-I and II when added to 
RPMI 1640 medium, fortified with selenium, hydro- 
cortisone, transferrin, and fl-estradiol. Labeled IGF-I 
and II bound to SH-SY5Y cells. The cross-reaction 
pattern of IGF-I, IGF-II, and insulin in competing 
with the binding of labeled IGF-I and IGF-II, respec- 
tively, indicated that SH-SY5Y cells express both type 
I and type II IGF receptors. Treatment of SH-SY5Y 
cells for 4 d with 12-O-tetradecanoylphorbol-13-ace- 
tate (TPA), which resulted in morphological and func- 
tional differentiation and growth inhibition, abolished 
the mitogenic response to both IGF-I and II. Concom- 
itantly, the binding of IGF-II disappeared almost to- 
tally, which offers a possible explanation for the re- 
duced biological response to IGF-II after TPA treat- 
ment. In contrast, the IGF-I binding in TPA-treated 
cells was only reduced to ~70% of the binding to 
control cells. It is therefore not excluded that the IGF- 
I receptor could be uncoupled by TPA, with persistent 
binding capacity for IGF-I. 
T 
HE human adrenergic neuroblastoma cells, SH-SY5Y, 
differentiate when exposed to biologically  active phor- 
bolesters (22, 24,  30) or retinoic acid (23). At nano- 
molar concentrations,  the most potent phorbol ester, 12-0- 
tetradecanoylphorbol- 13-acetate (TPA),~ induces an increase 
in the concentrations  of noradrenalin  and  neuron-specific 
enolase (22). Morphologically, the TPA-treated cells acquire 
long cell processes and an increased amount of  neurosecretory 
granula. TPA treatment also leads to increased resting mem- 
brane potential and the cells are depolarized by high concen- 
trations of potassium (1). 
TPA-treated SH-SY5Y cells are partially growth inhibited 
(22) and  have  a  low  ornithine  decarboxylase (ODC) (EC 
4. I. I. 17) activity, which cannot be stimulated by a change to 
fresh medium (16). ODC is the rate-limiting enzyme in the 
biosynthesis of polymines (8, 27) and during mitogenic stim- 
ulation of cultured cells, including SH-SY5Y ceils (16), the 
ODC activity is rapidly induced (l 8). By use of  the irreversible 
ODC inhibitor, a-difluoromethylornithine, an association be- 
tween inhibition of both ODC activity and cell proliferation 
has been found (Mattsson, M. E. K., and S. P~Iman, unpub- 
lished data). The lack of ODC response to serum in TPA- 
t Abbreviations  used in this paper: FCS, fetal calf serum; HSA, human serum 
albumin;  IGF,  insulin-like growth  factor;  ODC,  ornithine  decarboxyiase; 
SHTE-medium, RPMI  1640 medium supplemented with selenium (30 nM), 
hydrocortisone (10 nM), transferrin ( 100 ~g/ml), and B-estradiol (10 nM); ]'dr, 
thymidine; TPA, 12-O-tetradecanoylphorbol-I 3-acetate. 
treated cells could indicate that these cells have lost the ability 
to respond to the growth-promoting activity of serum. 
The  mitogenic effect of serum  in  different cell culture 
systems has been attributed to the polypeptides in the soma- 
tomedin  family and platelet-derived growth factor (7,  32). 
The two main forms of somatomedins, isolated from human 
serum, are insulin-like growth factor I (IGF-I) and insulin- 
like growth factor II (IGF-II) (25, 26). The polypeptide termed 
somatomedin C was recently shown to be identical to IGF-I 
(12), while the polypeptide termed  somatomedin  A differs 
from IGF-I by deamidation of glutamine in position 40 (5). 
An IGF-II homologue, multiplication-stimulating activity has 
been isolated from conditioned medium of  rat BRL-ceUs  (21 ). 
The present study shows that both IGF-I-and II promote 
growth of SH-SY5Y cells and that the mitogenic effect of 
these factors in TPA-differentiated cells is essentially lost. 
Furthermore, the binding sites for iGF-II, present in undiffer- 
entiated cells, disappear almost completely after TPA treat- 
ment.  This  cell system gives an  opportunity  to study the 
growth control  in differentiating SH-SY5Y neuroblastoma 
cells under defined conditions. 
Materials and Methods 
Chemicals 
Human IGF-I and IGF-II were isolated from serum as previously described (5). 
The proteins were labeled  with a251 using the lactoperoxidase method yielding 
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(Milwaukee, WI). A stock solution was made in ethanol and in the experiments 
the ethanol  concentration  never exceeded 0.1%. This concentration  had  no 
apparent effect on growth or differentiation of SH-SYSY cells. Human serum 
albumin (HSA) was from AB Kabi (Stockholm,  Sweden),/~-estradiol, hydro- 
cortisone,  and transferrin  were from Sigma Chemical  Co.  (St. Louis,  MO), 
insulin  was from Novo lndustri  AB (Copenhagen,  Denmark),  and selenious 
acid was from Kebo (Stockholm,  Sweden). Tritiated  thymidine  (2 Ci/mmol) 
was from The Radiochemieal Centre (Amersham Corp., UK). 
Cell Cultures 
The human adrenerglc  neuroblastoma  cell line, SH-SY5Y (2, 3), was kindly 
provided by Dr. June Biedler (Sloan-Kettering Institute, New York). The cells 
were routinely  grown  in  Eagle's minimum essential  medium supplemented 
with 10% fetal calf serum (FCS), penicillin (100 IU/ml), and streptomycin (50 
pg/ml) at 37"C in a 95% air, 5% COz-humidifled  incubator. 
In the experiments of thymidine incorporation,  106 cells were seeded per 3.5 
cm dish  (Falcon  Labwares, Grenoble,  France)  and cultured  for 4  d  in the 
medium described above. Before assay, the cells were washed twice and incu- 
bated for 2 d in RPMI-HSA medium (RPMI  1640 containing  5 mg HSA/ml). 
Then, the medium was replaced by 1 ml fresh RPMI-HSA medium containing 
the mitogens to be tested. At indicated times, the cells were pulsed for 1 h with 
0.2  uCi [3H]thymidine ([JH]Tdr) per dish. Thereafter,  the cells were washed 
twice in cold phosphate-buffered saline and precipitated with 10% cold trichlo- 
roacetic  acid.  The  precipitated  cells  were  washed  three  times with water, 
removed from the dish by 0.3 M NaOH and  1% SDS, and the radioactivity 
was counted  in a scintillation counter.  The number of cells per dish (-3.5 x 
106  cells in  nontreated  and  1.5  x  I(P  cells in  TPA-treated  cultures),  was 
determined  in parallel cultures. 
For determination  of cell proliferation,  5 x  104 cells were seeded in 3.5-cm 
culture dishes in 2 ml Eagle's medium supplemented with 10% FCS. The cells 
were allowed to plate  for  1 d  in this medium.  Different  concentrations  of 
growth factor in RPMI medium supplemented with selenium (30 nM), hydro- 
cortisone  (10 nM), transferrin  (100/~g/ml),  and B-estradiol (10 nM) (SHTE 
medium) (29), was added to the cells. SHTE medium alone could not stimulate 
ODC activity, [3H]Tdr incorporation  or proliferation of SH-SY5Y cells. After 
7  d,  with  change  to  fresh  medium at  day  4,  the  cells were  harvested  by 
trypsinization and viable (>92% of  the cells), Trypan blue-excluding cells were 
counted in a Biirker chamber. 
ODC Assay 
Cells (2 x  106/8.5-cm dish) were grown for 4 d in Eagle's medium with  10% 
FCS, which was replaced by fresh RPMI medium including the mitogen to be 
tested. Cells were harvested at indicated times and prepared for ODC assay as 
previously described by Mattsson et al. (16). Protein was determined according 
to a modified Lowry procedure (24). 
IGF-I and IGF-II Binding 
The binding studies were performed either at 5°C (A), using detached cells in 
suspension, or at 23"C (B), with cells still attached to the culture dish. 
(A) Nontreated  SH-SY5Y cells or cells treated for the indicated times with 
16  nM TPA were removed  from the culture  dish by EDTA treatment.  Cell 
aggregates were disrupted  mechanically  using a  Pasteur pipette  and the cells 
were suspended  in Eagle's medium containing  5 mg HSA  per ml (binding 
medium) to a final concentration  of 10* cells/100 u! medium.  Labeled IGF-1 
and IGF-II and various amounts of cold growth factors were incubated  with 
the cells for 6 h at 5°C (conditions  for optimal  IGF binding at 5°C [data not 
shown]). 100-el aliquots of the incubation  mixtures were layered over 1 ml of 
a mixture of  dibutylphthalate and dinonylphthalate  (at a 2:3 ratio) in Eppendorf 
tubes. Cell-bound IGF was separated from free IGF by spinning down the cells 
through the oil layer, at t3,000 rpm for 2 rain in an Eppendorf  centrifuge. The 
tips of the tubes were cut off and counted in a gammacounter. 
(B) Nontreated  cells were grown to confluency (-I.5 x  106 cells/well) in 
Linbro plates (Flow Laboratories, Inc., McLean, VA) with 24 wells. The cells 
were washed three times with binding medium and preincubated  in 0.5 ml of 
this  medium for  1 h.  Labeled  IGF-I or IGF-II were added  to the cultures 
together  with different  amounts of cold growth factors. After an incubation 
period  of l  h at 23°C, the  cells were washed  five times in ice-cold binding 
medium before lysis in 0.3 M NaOH and  1% SDS. The number of cells per 
well was determined  in parallel cultures. In the case of TPA-treated cells, these 
cultures were not confluent when assayed for binding of IGF. 
Results 
Activation of ODC and Thymidine Incorporation  by 
IGF-I and H in SH-SY5Y Cells before and after 
TPA Treatment 
The ODC activity in SH-SY5Y cells, grown for 4 d in presence 
of 10% FCS,  was low. Change to fresh medium containing 
FCS,  resulted in an increased ODC activity with maximal 
response after 6 h. Under the same initial conditions, IGF-II 
(30 ng/ml) in RPMI medium induced ODC activity of  similar 
duration  but  of higher magnitude than  the  ODC  activity 
induced by 10% FCS (Fig. 1). The kinetics of FCS-stimulated 
[3H]Tdr incorporation in SH-SY5Y cells is shown in Fig. 2. 
An increase in incorporated radioactivity could be detected 
after 13 h and the maximal incorporation rate was obtained 
between 19 and 25 h after the addition of FCS. The control 
medium, RPMI-HSA, did not cause any obvious change in 
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Figure 1. ODC activity in SH-SY5Y cells stimulated with FCS or 
IGF II. Cells were grown for 4 d in medium supplemented with 10% 
FCS. After a  change to fresh RPMI  1640  medium containing  10% 
FCS (&), 30 ng IGF-II/ml (O), or without any addition (ll), the cells 
were  harvested at  the  indicated  times for determination  of ODC 
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Figure 2.  3H-Tdr incorporation in  SH-SY5Y cells stimulated with 
FCS or IGF-II. Cells were grown for 4 d and then serum depleted for 
2  d  before change to RPMI-HSA medium (I), supplemented with 
10%  FCS (&) or 30  ng IGF-II/ml (0).  At the  indicated  times, the 
cells were pulsed for 1 h  with 3H-Tdr (0.2 pCi/ml) and processed as 
described in Materials and Methods. The number of cells per dish 
was  determined  in  parallel  cultures,  Each  point  is  the  mean  of 
triplicate cultures +SD. 
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medium, caused an increase of [3H]Tdr incorporation during 
the same time period but of lower magnitude than that found 
in FCS-stimulated cells (Fig.  2). IGF-I could also induce the 
activation of ODC and [3H]Tdr incorporation with a similar 
kinetics as for the stimulation by IGF-II (not shown). 
The activation of ODC by IGF-I or IGF-II was concentra- 
tion dependent with a  maximal response at concentrations 
above 10 ng/ml (Fig.  3). The activity induced by IGF-I was 
similar to that induced by IGF-II. Similarly, the stimulated 
[3H]Tdr  incorporation  was  concentration  dependent  with 
maximal response at concentrations above l0 ng/ml of IGF- 
I or IGF-II (Fig. 3). 
After 4  d  of treatment with  16  nM  TPA, when the SH- 
SYSY cells were morphologically and functionally differen- 
tiated,  IGF-I and II in RPMI medium caused only a  slight 
induction of ODC activity. Similarly, IGF-I and II had no or 
very little stimulatory effect on [3H]Tdr incorporation of cells 
treated for 4 d with TPA (Fig. 3). 
Proliferation of  SH-SYSY Cells in a Defined 
Medium Containing IGF-II 
To  investigate  the  mitogenicity  of IGF polypeptides,  SH- 
SYSY cells were exposed to different concentrations of IGF- 
II in RPMI or RPMI-HSA medium, but after 5-6 d in culture, 
the cells began to detach from the culture dish. However, the 
SH-SYSY cells could be grown for at least 2  mo in SHTE 
medium together with a high concentration of insulin (5 #g/ 
ml). IGF-II in combination with SHTE medium supported 
proliferation of SH-SYSY cells.  The proliferation rate was 
dose dependent,  with  maximal growth at concentration  of 
10-30 ng IGF-II/ml (Fig. 4). The dose dependency of prolif- 
eration was similar to the activation of ODC and thymidine 
incorporation. However, the proliferation rate was lower than 
in cells grown in Eagle's medium containing  10% FCS (not 
shown).  Also  10-30  ng IGF-I/ml in  SHTE medium could 
support proliferation of the SH-SYSY cells (not shown). 
The  decrease in  IGF mediated inducibility  of the  ODC 
activity and the [3H]Tdr incorporation after TPA treatment 
indicated that these cells no longer could respond to IGF-I or 
II with proliferation. Experiments to verify this failed, because 
the  TPA-treated  cells  adhered  poorly  in  SHTE-IGF-I or 
SHTE-IGF-II medium and it was not possible to follow the 
proliferation for a longer period. 
IGF-I and IGF-II Binding to SH-SY5Y Cells before 
and after TPA Treatment 
Cells, incubated with ~2sI-IGF-I  or II at 5"C or 23"C displayed 
maximal binding after 6 h and 1 h, respectively (not shown). 
Both labeled IGF-I and II bound specifically to the SH-SYSY 
cells at 5"C (Fig. 5). IGF-II was slightly less potent than IGF- 
I in displacing labeled IGF-I, and insulin cross-reacted with 
IGF-I for its receptor. IGF-II was considerably more potent 
than IGF-I in displacing labeled IGF-II (Fig. 5 B). Physiolog- 
ical concentrations of insulin did not cross-react with IGF-II 
while a displacement could be seen at pharmacological con- 
centrations (100-3,000 ng/ml). 
The specific binding of IGF-II to SH-SYSY cells was vir- 
tually lost after TPA treatment for 4 d (Fig. 6). The changes 
in the kinetics of the binding of IGF-I and II to TPA-treated 
SH-SY5Y cells is shown  in  Fig.  7.  After  30  rain  of TPA 
treatment, a slight decrease in IGF-II binding was seen and 
prolonged TPA treatment resulted in a further reduction of 
the IGF-II binding, with 15 and 5% left of the initial binding, 
after  24  and  96  h  of treatment,  respectively. In  contrast, 
specific binding of IGF-I was reduced to ~70% within 30 rain 
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Figure 3. Stimulation of ODC ac- 
tivity and 3H-Tdr incorporation by 
IGF-I and IGF-II in  non-treated 
and TPA-treated SH-SY5Y cells. 
The  IGF-induced  response  has 
been compared to the stimulation 
obtained when no IGF was pres- 
ent. Cells were grown for 4 d with 
(O) or without  (0)  16  nM TPA 
present in FCS-supplemented me- 
dium.  (.4) Fresh  RPMI  medium 
with IGF-I in concentrations be- 
tween 3-30 ng/ml was added and 
the cells were harv~ted after 5 h 
for determination of  ODC activity. 
Each point is the mean of  triplicate 
samples +SD. (B) The cells were 
serum depleted for 2 d and then 
stimulated  with RPMI-HSA me- 
dium with different IGF-I concen- 
trations. After 23 h, the cells were 
pulsed for  1 h  with 3H-Tdr and 
processed  as described in Materials 
and Methods. Each point  is the 
mean  of duplicate  cultures.  (C) 
Activation  of  ODC  by  IGF-II. 
Conditions  as in  A.  (D)  3H-Tdr 
incorporation induced by IGF-II. 
Conditions as in B. 
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Figure 4.  (.4)  ODC  activity,  (B)  3H-Tdr  incorporation,  and  (C) 
proliferation of SH-SY5Y cells stimulated with 1-30 ng/ml of IGF- 
II. (A and B) Conditions as in Fig. 3.4 and B. (C) Ceils were plated 
in FCS-supplemented medium. ARer l  d, it was changed to SHTE 
medium with different concentrations of IGF-II. The cells in duplicate 
cultures were counted after 7 d of culture. 
after TPA treatment. Prolonged treatment did not result in a 
further reduction of IGF-I binding. 
Discussion 
The growth-promoting effect of physiological concentrations 
of polypeptide hormones is mediated through specific mem- 
brane-bound  receptors.  Changes  in  the  expression  and/or 
structure of these  receptors could be a  mechanism for the 
control of growth of SH-SY5Y cells. These cells proliferate in 
FCS-supplemented medium and decrease their proliferation 
rate markedly during TPA-induced differentiation (22,  24). 
In such cells, ODC activity was no longer inducible by FCS 
(16). In the present study we show that SH-SY5Y cells have 
binding sites for IGF-I and II; growth factors present in serum. 
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Figure 5.  Binding of ~25I-IGF-I and  ~25I-IGF-II to SH-SYSY  cells. 
Cells were incubated in binding medium at 5°C for 6 h with labeled 
IGF (8,000 cpm/10  ~ cells) and different amounts of unlabeled IGF-I 
(O), IGF-II (O), or insulin (D).  The cell-bound radioactivity in  106 
cells was determined  after the cells had been  separated  from free 
tracer as described in Materials and Methods.  (.4) Bound t25I-IGF-I. 
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Figure 6. Binding of '25I-IGF-II to non-treated and TPA-treated SH- 
SY5Y cells. The cells were grown for 4 d with (0) or without ((3)  16 
nM TPA. The cultures were incubated with 125I-IGF-II (25,000 clam/ 
well) and different amounts of unlabeled IGF II at 23°C for 1 h. The 
cell-bound radioactivity was measured  in duplicates after the cells 
had been washed and solubilized. The number of cells was counted 
in parallel cultures. 
Furthermore, pure human IGF-I and II stimulated the ODC 
activity and thymidine incorporation in SH-SYSY cells, be- 
fore but not after TPA treatment. The defined SHTE medium 
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Figure 7. Specific 125I-IGF-I  and II binding to SH-SY5Y cells treated 
by TPA for various time periods. After the treatment with  16 nM 
TPA, the cells were harvested and split into two samples for incuba- 
tion  at  5"C with  IGF-I and  IGF-II as detailed in  Materials and 
Methods and Fig. 5. The binding of IGF-I ((3) and IGF-II (11) was 
expressed as % of the binding to non-treated SH-SY5Y cells. 
supplemented with these factors could support the prolifera- 
tion of SH-SY5Y cells. 
Although  IGF-I or IGF-II, in SHTE medium, promoted 
proliferation of SH-SY5Y cells over several cell divisions, this 
medium did not provide optimal growth conditions.  Apart 
from a lower proliferation rate in SHTE-IGF-II medium, as 
compared with medium containing 10% FCS, the cells tended 
to detach from the culture dish when grown for more than a 
week. Thus, serum is superior to SHTE-IGF-II medium in 
stimulating DNA synthesis and maintaining growth. Serum 
contains other growth factors such as platelet-derived growth 
factor. However, the SH-SY5Y cells lack binding sites for this 
factor (9) and the higher potency of serum has to be attributed 
to unknown serum growth and/or maintenance factors. 
The  low  concentrations  (10-30  ng/ml)  of IGF-I and  II 
required for maximal stimulation of ODC activity and thy- 
midine incorporation could suggest that these growth factors 
act through somatomedin/IGF receptors. Two types of so- 
matomedin/IGF receptors have been characterized. The type 
I receptor prefers IGF-I over IGF-II and recognizes insulin, 
whereas the type II receptor prefers IGF-II over IGF-I and 
does not recognize insulin (21). The cross-reaction pattern of 
these factors indicates that the SH-SY5Y cells express both 
type I and type II receptors. 
TPA treatment markedly decreased the IGF-I and II-in- 
duced stimulation of  ODC activity and DNA synthesis despite 
remaining binding of IGF-I. The reduced binding of IGF-II 
to  TPA-treated  cells  offers  a  possible  explanation  for  the 
absence of a mitogenic response. The remaining IGF-I bind- 
ing to  TPA-treated cells could  indicate  that the  biological 
response to IGF-I is mediated via the type II receptor. How- 
ever, it could also be explained by a TPA-induced uncoupling 
of type I receptors. Such a TPA effect has been described for 
the al-adrenergic receptor in  hamster smooth muscle cells, 
where TPA treatment results in a receptor uncoupling from 
inositol phospholipid metabolism, despite an unaltered ago- 
nist binding (14).  Therefore, the present results cannot eluci- 
date whether the mitogenic effects of IGF-I and II in non- 
treated cells are mediated through the IGF-I and/or IGF-II 
receptor. 
Biologically active  phorbol  esters  and  other  tumor  pro- 
rooters, like mezerein, saccharin, and cyclamate, have previ- 
ously been shown to diminish the binding of several other 
growth factors such as epidermal growth factor (4,  13,  28), 
insulin (6, 31), nerve growth factor (10), and transferrin (17). 
The decreased binding has been attributed to either reduced 
receptor affinity (4, 6,  10, 28) or decreased number of recep- 
tors (13,  17). 
At present, no general mechanism can explain the effect of 
phorbol esters on expression of growth factor receptors, but 
TPA  has  been  shown  to  enhance  the  phosphorylation of 
insulin, IGF-I, epidermal growth factor, and transferrin recep- 
tors, respectively (11,  17,  19). Furthermore, in a phosphoryl- 
ation-dependent process, TPA causes a reversible internaliza- 
tion of the transferrin receptor complex (17).  Whether the 
decreased IGF-II binding observed in TPA-treated SH-SY5Y 
cells is a  direct  TPA  effect or is due  to the  TPA-induced 
differentiation is not clear. The fact that most of the IGF-I 
and IGF-II  binding is still present after 1.5 h of  TPA treatment 
could indicate that mechanisms other than those operating in 
the internalization of the transferrin receptor (e.g., phospho- 
rylation of the receptor by protein kinase C) (17) are acting 
in  TPA-treated SH-SY5Y cells.  There are reports of other 
types of cells that lose their binding sites for growth factors 
during differentiation (15, 20). 
In conclusion, IGF-I and II are shown to be growth factors 
for SH-SY5Y cells although they cannot completely replace 
serum. The decrease in IGF-II binding after TPA treatment 
offers a  possible mechanism for growth control in differen- 
tiating neuroblastoma cells. 
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